Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYPERSHU trial of eculizumab in hypertensive emergency-associated hemolytic uremic syndrome
2024-516402-32-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of eculizumab in hemolytic uremic syndrome (HUS) and hypertensive emergency (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Primary composite response to therapy. Planned start Feb 2024; status: authorised.
02
Drugs
eculizumab
03
Conditions
hemolytic uremic syndrome (HUS)hypertensive emergency
Beyond the preview
Go deeper on 2024-516402-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516402-32-00.